Compare Citius Pharmaceuticals Inc (CTXR) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Jumia Technologies AG - ADR trades at $6.84 (market cap $848.39M). The key difference: Jumia Technologies AG - ADR is far larger — about 58× Citius Pharmaceuticals Inc's market cap, and Jumia Technologies AG - ADR is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | JMIA | |
|---|---|---|
Market Cap | $14.64M | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $14.60 |
52-Week Low | $0.53 | $4.45 |
Enterprise Value | $10.86M | $795.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
JMIA trades at $6.71, down 4.28% today, amid bearish technical signals despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, targeting 2027 profitability. Recent Q1 2026 results beat GMV guidance with 39% revenue growth, though EPS missed expectations. Cash flow turned positive in 2024-2025 after years of negative net flows.
Outlook remains speculative with high execution risk despite 71% analyst buy ratings. The path to profitability depends on successful African market expansion and cost management. Key risks include persistent losses, competitive pressures, and macroeconomic challenges in operating markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
